Eli Lilly and Company
@EliLillyandCo
Uniting caring with discovery to create medicines that make life better worldwide. Lilly’s official account (formerly LillyPad)
Joined July 2010
1.2K Following 145.5K Followers
Adults with type 2 diabetes on our investigational triple agonist saw significant A1C reductions at 40 weeks in the TRANSCEND-T2D-1 trial. Results presented today at #ADA2026# and published simultaneously in @TheLancet. Read more:
Show more
